WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that the Company will hold a conference call at 8:00 a.m. ET on Monday, December 14, 2009, to review the clinical data reported on TAP compounds at the AACR-NCI-EORTC, American Society of Hematology, and San Antonio Breast Cancer Symposium medical meetings held in November/December 2009. This call will include comments by ImmunoGen’s Chief Executive Officer, Daniel Junius, Chief Medical Officer, James O’Leary, MD, and Chief Scientific Officer, John Lambert, PhD.
